Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 11/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.94 |
| ▸ | RAD52 | P43351 | 2/20 | 0.94 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.61 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.61 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372738 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL15965174 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL8381473 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL8386909 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL1172093 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL8383501 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL668301 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL1171874 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL6375709 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL8386779 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1019 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661968-A1 | DIHYDROTRIAZINE COMPOUND AND COMPOSITION FOR USE IN PODOLOGY, IN THE PROPHYLAXIS AND/OR TREATMENT OF FOOT DISORDERS, THE TREATMENT OF TATTOOS AND/OR TATTOO WOUNDS AND THE TREATMENT OF A PIERCING AND/OR PIERCING WOUNDS | B. Braun Melsungen AG (DE) | 2025-12-17 | — | — | EP | claimed |
| EP-4661674-A1 | ANTIMICROBIAL MEDICAL PRODUCT | B. Braun Melsungen AG (DE) | 2025-12-17 | — | — | EP | claimed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | claimed |
| WO-2025075299-A1 | NANOFIBER FILTER AND METHOD FOR MANUFACTURING SAME | 엘지전자 주식회사 | 2025-04-10 | — | — | WO | claimed |
| EP-4531576-A1 | AQUEOUS DETERGENT AND/OR DISINFECTANT COMPOSITION | Sodel (FR) | 2025-04-09 | — | — | EP | claimed |
| CN-119771119-A | Organic waste gas absorption liquid and application thereof as absorbent in building material combustion test | 广东省建筑材料研究院有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119701581-A | Flue gas purification system for testing combustion performance of building materials | 广东省建筑材料研究院有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119150470-A | Gear fatigue life prediction model and method for establishing same | 重庆大学 | 2024-12-17 | — | — | CN | claimed |
| CN-119125345-A | Method for dissolution curve of fumace-thioxetine tablet | 山西远扬医药科技有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-118806790-A | Cationic nano-enzyme and preparation method and application thereof | 云南省第一人民医院 | 2024-10-22 | — | — | CN | claimed |
| WO-1994025053-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS, INC. (US) | 1994-11-10 | — | — | WO | claimed |
| EP-0480270-B1 | Arylsulfides and process for their fabrication | CASSELLA FARBWERKE MAINKUR AG (DE) | 1994-05-04 | — | — | EP | claimed |
| US-5274184-A | Aryl sulphide, aryl sulphoxide and aryl sulphone compounds | CASSELLA AKTIENGESELLSCHAFT (DE) | 1993-12-28 | — | — | US | claimed |
| EP-0480270-A1 | Arylsulfides and process for their fabrication | CASSELLA Aktiengesellschaft (DE) | 1992-04-15 | — | — | EP | claimed |
| EP-0238994-B1 | PROCESS FOR PREPARING HIGH PURITY DERMATAN-SULPHATE, AND PHARMACEUTICAL COMPOSITIONS WICH CONTAIN IT | MEDIOLANUM FARMACEUTICI s.r.l. (IT) | 1991-07-17 | — | — | EP | claimed |
| EP-0374258-A1 | HIGH REFRACTIVE INDEX LENS AND METHOD FOR ITS PRODUCTION | MITSUI CHEMICALS, INC. (JP) | 1990-06-27 | — | — | EP | claimed |
| EP-0131020-B1 | METHOD FOR THE VOLUMETRIC DIFFERENTIATION OF LEUKOCYTES | COULTER ELECTRONICS INC. (US) | 1989-08-02 | — | — | EP | claimed |
| EP-0271839-A2 | Casting polymerisation process for preparing sulfur-containing urethane resin lens | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1988-06-22 | — | — | EP | claimed |
| EP-0244717-A2 | Process for the preparation of 2,3-epoxyamides | BAYER AG (DE) | 1987-11-11 | — | — | EP | claimed |
| US-3983175-A | FROM ORGANIC HALIDE AND A KETONE | KURARAY CO., LTD. (JA) | 1976-09-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | DNM1 1600/4885HTT 131/4885KMT2A 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.